{"nctId":"NCT04322968","briefTitle":"Ketamine Infusion for Comorbid PTSD and Chronic Pain","startDateStruct":{"date":"2018-01-09","type":"ACTUAL"},"conditions":["PTSD","Chronic Pain"],"count":41,"armGroups":[{"label":"Chronic pain with PTSD+IV ketamine infusion","type":"EXPERIMENTAL","interventionNames":["Drug: A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms."]},{"label":"Chronic pain with PTSD+IV ketorolac infusion","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms."]},{"label":"Chronic pain without PTSD+IV ketamine infusion","type":"EXPERIMENTAL","interventionNames":["Drug: A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms."]},{"label":"Chronic pain without PTSD+IV ketorolac infusion","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms."]}],"interventions":[{"name":"A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms.","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nVeterans with chronic pain as defined by having any chronic pain beyond 6 months in duration with and without PTSD diagnoses (participants must meet DSM-V criteria for current post-traumatic stress disorder (PTSD) and have received a diagnosis of PTSD greater than or equal to 3 months prior to assessment); they also will be either free of concomitant use of psychotropic and/or pain medications for at least 6 weeks or on stable doses of those medications within the last 6 weeks prior to randomization and for the duration of the study; if applicable, current frequency and duration of psychotherapy sessions must remain stable for at least 6 weeks prior to beginning of the study.\n\nExclusion Criteria:\n\nInability to speak English, inability or unwillingness to provide written informed consent; moderate-to-severe cognitive impairment (Mini-Mental State Examination scores\\<20 administered by a trained clinician); current or lifetime history of psychotic or bipolar disorder; current bulimia or anorexia nervosa, alcohol abuse or dependence in the previous 3 months; serious unstable medical illness or sleep apnea; HTN, prolonged QT interval, peptic ulcer disease or recent history of GI-bleed, renal insufficiency, active substance use disorder, active suicidal or homicidal ideation on presentation; pregnancy (confirmed by baseline lab test), the initiation of female hormonal treatments within 3 months of screening, or inability or unwillingness to use a medically accepted contraceptive method for the duration of the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Impact of Event Scale-Revised (IES-R)","description":"Severity of PTSD symptoms; items are rated on a 5-point scale ranging from 0 (\"not at all\") to 4 (\"extremely\"). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.33333333","spread":"17.27715254"},{"groupId":"OG001","value":"37","spread":"15.77973384"},{"groupId":"OG002","value":"10.44444444","spread":"14.34495653"},{"groupId":"OG003","value":"15.64705882","spread":"17.05484233"}]}]}]},{"type":"PRIMARY","title":"Visual Analogue Scale (VAS)","description":"Severity of chronic pain symptoms; using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the \"no pain\" anchor and the patient's mark, providing a range of scores from 0-100; a higher score indicates greater pain intensity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.22222222","spread":"24.69705336"},{"groupId":"OG001","value":"49.66666667","spread":"23.44141634"},{"groupId":"OG002","value":"29.88888889","spread":"24.15286962"},{"groupId":"OG003","value":"38.70588235","spread":"28.12197696"}]}]}]},{"type":"SECONDARY","title":"Impact of Event Scale-Revised (IES-R)","description":"Severity of PTSD symptoms; items are rated on a 5-point scale ranging from 0 (\"not at all\") to 4 (\"extremely\"). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.22","spread":"22.60"},{"groupId":"OG001","value":"33.66666667","spread":"20.43281674"},{"groupId":"OG002","value":"11.44","spread":"17.47"},{"groupId":"OG003","value":"13.41","spread":"16.84"}]}]}]},{"type":"SECONDARY","title":"Visual Analogue Scale (VAS)","description":"Severity of chronic pain symptoms; using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the \"no pain\" anchor and the patient's mark, providing a range of scores from 0-100; a higher score indicates greater pain intensity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.22","spread":"31.59"},{"groupId":"OG001","value":"52.88","spread":"21.55"},{"groupId":"OG002","value":"43.33","spread":"19.28"},{"groupId":"OG003","value":"48.23","spread":"21.72"}]}]}]},{"type":"SECONDARY","title":"Brief Pain Inventory (Short Form)","description":"Severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week; No scoring algorithm, but \"worst pain\" or the arithmetic mean of the four severity items can be used as measures of pain severity (a range of 0-10, with 10 being worse scores); the arithmetic mean of the seven interference items can be used as a measure of pain interference (a range of 0-10, with 10 being worse scores). The total score is reported for severity items and interference items, which range from 0-40 and 0-70, respectively. Higher values represent worse outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.62","spread":"24.03"},{"groupId":"OG001","value":"25.66","spread":"20.32"},{"groupId":"OG002","value":"9.62","spread":"7.44"},{"groupId":"OG003","value":"28.33","spread":"21.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.75","spread":"10.55"},{"groupId":"OG001","value":"14.66","spread":"9.53"},{"groupId":"OG002","value":"12.75","spread":"5.44"},{"groupId":"OG003","value":"22.66","spread":"9.13"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Patient-Rated Inventory of Side Effects (PRISE20)","description":"Patient self report used to qualify side effects by identifying and evaluating the tolerability of each symptoms; 20 items; higher scores mean worse side effects","paramType":null,"dispersionType":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Clinician-Administered Dissociative States Scale (CADSS)","description":"Dissociative, psychotomimetic, and manic symptoms; 27-item scale with 19 subject-rated items and 8 items scored by an observer; higher scores mean worse present-state dissociative symptomatology","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":[]}}}